Search results
The FDA Should Reject MDMA Therapy—but Not for the Reasons You Think
Slate· 4 days agoOn June 4, a panel advising the Food and Drug Administration voted 9–2 that Lykos Therapeutics, a...
Why FDA Panel Rejected MDMA Therapy—And What’s Next For Psychedelic Medicine
Forbes· 4 days agoHigh hopes that psychedelic medicines were finally on the pathway to regulation were dashed last...
CCHR Applauds FDA Panel Rejecting MDMA Psychedelic for Mental Health Treatment
Digital Journal· 12 hours agoA panel of experts from the Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee has overwhelmingly rejected the use of the psychedelic MDMA, also ...
FDA panel rejects MDMA-assisted therapies for PTSD despite high hopes from veterans
Fox News· 4 days agoA U.S. Food and Drug Administration (FDA) panel rejected MDMA-based treatments for post-traumatic...
Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics
WUSF 89.7· 4 days agoIt was a harsh public reckoning over the drug’s future and a deflating moment for those involved in ...
‘Magic mushrooms’ may soon be used for therapy in San Diego County
KSWB articles via Yahoo News· 4 days agoWhether or not the bill passes remains to be seen. Nonetheless, the push for psychedelic therapy...
Psychedelics change how we see the world. A UC Berkeley study aims to find out why. - Berkeley News
UC Berkeley NewsCenter· 6 days agoIn the experiment, healthy human participants will ingest psilocybin, a compound found in ...
FDA rejects promising new therapy for PTSD, veteran advocates sound off: ‘Big gut punch’
BizPac Review· 4 days agoA Federal Drug Administration advisory panel has voted against authorizing MDMA-assisted therapy for PTSD. MDMA, more commonly known as ecstasy, is a Schedule ...
UC Berkeley To Enlist Human Subjects in Groundbreaking Psilocybin Study
High Times· 3 days agoThe study will examine how psilocybin changes the way our brain interprets information that we see and pushes us out of our normal state of mind. The UC Berkeley Center for the Science of < ...
With MDMA debate spreading beyond biotech, Lykos CEO tries to dispel efficacy, safety concerns
FierceBiotech· 4 days agoA week after an FDA committee declined to support an midomafetamine (MDMA) treatment for...